Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030054/S435

Quartet; QuickFlex Micro

ABBOTT MEDICAL · Decision date Feb 19, 2026

FDA DECISIONP030054/S435

What did the FDA approve?

FDA records P030054/S435 as a supplement to PMA P030054, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Feb 19, 2026.

FDA approval order statement

an alternative sterilization site (Cycle 100 in Chamber 1 and 2, Abbott, Arecibo, PR) for analytical test articles (non-finished goods) comprising several cardiac leads and Aveir Leadless Pacemakers Monolithic Controlled Release Devices (MCRDs)
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Feb 19, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P030054/S435
Regulatory pathway
PMA supplement
Product code
NIK
Decision code
APPR
Decision date
Feb 19, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).

Product code
NIK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P030054/S435 received

    Application receipt date recorded by FDA.

  2. P030054/S438 · Related supplement

    Avant (CDHFA700Q, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800T CDHFA600Q, CDHFA600T); Gallant (CDHFA500Q, CDHFA500T);

  3. P030054/S436 · Related supplement

    Quartet 1456Q, 1457Q, 1458Q, 1458QL; Avant HF CDHFA700B, CDHFA700D, CDHFA700Q, CDHFA700T; Gallant HF CDHFA500B, CDHFA

  4. P030054/S439 · Related supplement

    Quartet and QuickFlex µ Left Heart Leads

  5. P030054/S441 · Related supplement

    Avant (CDHFA700Q, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800T CDHFA600Q, CDHFA600T); Gallant (CDHFA500Q, CDHFA500T);

  6. P030054/S435 · FDA decision

    135 Review Track For 30-Day Notice

  7. P030054/S443 · Related supplement

    Avant (CDHFA700Q, CDHFA700B, CDHFA700D, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800B, CDHFA800D, CDHFA800T); Gallant (

  8. P030054/S442 · Related supplement

    Promote/+/RF/Q, Promote Accel, Promote Quadra, Unify, Unify Assura, Unify Quadra, Quadra Assura, Epic+/HF/HF+/II HF/II+

  9. P030054/S444 · Related supplement

    Optisure Leads (LDA210, LDA210Q, LDA220Q, LDP210Q, LDP220Q, LDA230Q, LDP230Q); Quartet Leads (1456Q, 1457Q, 1458Q, 1456Q

  10. P030054/S445 · Related supplement

    Avant (CDHFA700Q, CDHFA700T, CDHFA700D); Neutrino NxT (CDHFA800Q, CDHFA800T, CDHFA800B, CDHFA800D, CDHFA600Q, CDHFA600T,

  11. P030054/S440 · Related supplement

    Promote/+/RF/Q, Promote Accel, Promote Quadra, Unify, Unify Assura, Unify Quadra, Quadra Assura, Epic+/HF/HF+/II HF/II+

  12. P030054/S446 · Related supplement

    Avant (CDHFA700Q, CDHFA700B, CDHFA700D, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800B, CDHFA800D, CDHFA800T, CDHFA600Q,

Timeline entries are records held by MedtechLedger for P030054. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030054

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementAug 4, 2025FDA
ABBOTT MEDICALPMA supplementAug 27, 2025FDA
ABBOTT MEDICALPMA supplementNov 20, 2025FDA
ABBOTT MEDICALPMA supplementFeb 13, 2026FDA
ABBOTT MEDICALPMA supplementMar 27, 2026FDA
ABBOTT MEDICALPMA supplementApr 24, 2026FDA
ABBOTT MEDICALPMA supplementApr 24, 2026FDA
ABBOTT MEDICALPMA supplementJul 9, 2026FDA
ABBOTT MEDICALPMA supplementJul 21, 2026FDA
ABBOTT MEDICALPMA supplementAug 12, 2026FDA

Explore the linked device profile

Other records with product code NIK

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91335

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records